Aiping H Young

This inventor holds 19 USPTO granted patents and 2 published patent applications, plus 3 CIPO patents and 6 EPO patents. Top assignees: Genesense Technologies Inc., Lorus Therapeutics Inc., Aptose Biosciences Inc.. Active years: 1999-2018.

USPTO Granted Patents = 19 (Patent Applications = 2)

% Patents Active = 52.6

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 1)

Average Co-Inventor Count = 2.7

ph-index = 6

Forward Citations = 121(Granted Patents)

Location History:

Winnipeg, CA (1999)
North York, CA (2003 - 2013)
Toronto, CA (2000 - 2018)

Company Filing History:

7 out of 8

Genesense Technologies Inc.

patents

7 out of 10

Lorus Therapeutics Inc.

patents

2 out of 6

Aptose Biosciences Inc.

patents

4. 1 out of 1

Aptose Boisciences Inc.

patent

5. 1 out of 1

Erin Mills Biotech Inc.

patent

6. 1 out of 834,411

Other

patents

Years Active: 1999-2018

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10080739 - Aryl imidazoles and their use as anti-cancer agents (2018-09-25),

2. 9309247 - 2-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the treatment of cancer (2016-04-12),

3. 8987305 - 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents (2015-03-24),

4. 8969372 - Aryl imidazoles and their use as anti-cancer agents (2015-03-03),

5. 8394815 - 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents (2013-03-12),

6. 8394418 - Combination preparation of a biological response modifier and an anticancer agent and uses thereof (2013-03-12),

7. 8287851 - Use of interleukin 17E for the treatment of cancer (2012-10-16),

8. 8148392 - 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer (2012-04-03),

9. 7968526 - Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in the treatment of cancer (2011-06-28),

10. 7884120 - 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents (2011-02-08),

11. 7405205 - Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase (2008-07-29),

12. 7223849 - Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth (2007-05-29),

13. 7087580 - Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth (2006-08-08),

14. 6610539 - Antisense oligonucleotide sequences as inhibitors of microorganisms (2003-08-26),

15. 6566514 - Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth (2003-05-20),

Title: Aiping H Young: Innovator in Anti-Cancer Research

Introduction

Aiping H Young, based in Toronto, Canada, is a prominent inventor known for his significant contributions to cancer therapeutics. With a total of 19 patents to his name, his work focuses on developing innovative compounds that have the potential to combat various types of cancer.

Latest Patents

Young's most recent patents include groundbreaking inventions such as "Aryl imidazoles and their use as anti-cancer agents." This patent presents therapeutically effective 2,4,5-trisubstituted imidazole compounds, along with methods for preparing these compounds and their pharmaceutical applications. These compounds are designed for use as anti-cancer agents, demonstrating a wide range of substituents that can optimize their therapeutic efficacy.

Additionally, he has developed "2-substituted imidazo[4,5-D]phenanthroline derivatives and their use in the treatment of cancer." This invention focuses on compounds that inhibit the proliferation of various cancer cell types, including renal, pancreatic, prostate, colon, leukemia, brain tumors, and non-small cell lung cancer. These innovations reflect his dedication to advancing cancer treatment through chemical synthesis and medicinal chemistry.

Career Highlights

Throughout his career, Aiping H Young has collaborated with notable companies in the biotechnology sector, including Genesense Technologies Inc. and Lorus Therapeutics Inc. His work in these organizations has positioned him as a leader in cancer research and the development of novel therapeutics.

Collaborations

Young has worked alongside esteemed colleagues Jim A Wright and Yoon S Lee. Their collective expertise has fostered an environment of innovation and has contributed significantly to advancements in anti-cancer therapies.

Conclusion

Aiping H Young's contributions to the field of cancer research through his patents demonstrate his commitment to fighting this devastating disease. His innovative compounds and methodologies pave the way for future advancements, offering hope for improved treatment options for cancer patients worldwide.